Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05893693
Other study ID # CT0594CP-CG6020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 12, 2023
Est. completion date January 1, 2026

Study information

Verified date May 2023
Source Shanghai Tongji Hospital, Tongji University School of Medicine
Contact Aibin Liang
Phone +8618601670600
Email lab7182@tongji.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia


Description:

This is an open-label, single arm, dose-escalation clinical study, to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date January 1, 2026
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients and legally acceptable representative must have voluntarily signed ICF and willing to complete the study procedure, after fully understanding of the study. 2. Age = 18 years and = 75 years, male or female. 3. The patients, with MM or Plasma Cell Leukemia, who have received regimens and have medical records in the past. 4. According to the IMWG consensus for relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia, the disease is in a progressive state 5. Subjects should have measurable disease. 5.1 Serum M protein = 5 g / L; 5.2 24-hour urinary M-protein = 200 mg; 5.3 The serum free light chain (sFLC) ratio was abnormal and the involved FLC = 100mg/L in patients with light chain multiple myeloma whose serum or urinary M protein levels did not meet the assessable criteria. 5.4 Circulating plasma cells =2% 6. Expected survival > 12 weeks. 7. Eastern Cooperative Oncology Group (ECOG) scores 0-1. 8. Subjects should have adequate function in hemostatic and liver and kidney. 9. Women of childbearing age must undergo a serum pregnancy test with negative results at screening and before lymphodepletion and be willing to use an effective and reliable method of contraception for at least 1 year after study treatment. All female subjects are prohibited from egg donation within 1 year after study treatment. 10. Men must be willing to use an effective and reliable method of contraception for at least 1 year after study treatment if they have sexual activity with women of childbearing potential. All male subjects are prohibited from sperm donation within 1 year after study treatment . Exclusion Criteria: 1. Pregnant or lactating women. 2. Subjects positive for any following tests: human immunodeficiency virus (HIV) antibody, Treponema pallidum (syphilis) antibody, CMV(IgM),EBV; 3. Active hepatitis B and/or active hepatitis C (HCV RNA positive); Those who are positive for hepatitis B surface antigen and/or core antibodies but whose HBV-DNA test is within normal limits may be enrolled. 4. Subjects with any uncontrolled active infection (Except for prophylactic treatment). 5. Subjects with AEs from previous treatment that have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) = 1, excluding hair loss and other events that the treating physician considers as tolerable. 6. Subjects who have received autologous BCMA CAR-T therapy 7. Subjects who have received allogeneic stem cell transplantation for MM. 8. Subjects who have received autologous stem cell transplantation less than 12 weeks before ICF. 9. Subjects who have received any anti-MM treatment 14 days before ICF; the subjects are eligible to participate in the study regardless of the radiotherapy end date if the radiation area less than 5% of whole body. 10. Subjects who have received systemic glucocorticoids within 7 days before infusion, except inhaled steroids. 11. Subjects who have been received live attenuated vaccine within 8 weeks or inactivated vaccine within 4 weeks before lymphodepletion. 12. Subjects have severe allergy history. 13. Subjects who have any uncontrolled disease conditions within 6 months prior to the screening. 14. LVEF < 50% 15. Blood oxygen saturation that can only be maintained at > 95% by oxygen inhalation. 16. Subjects known to have active autoimmune diseases including but not limited to psoriasis, rheumatoid arthritis and other conditions that require long-term immunosuppressive therapy. 17. Subjects with malignant tumors that have not been cured in the past 5 years or at the same time, except for very low malignant tumors. 18. Subjects who have central nervous system (CNS) metastases or symptomatic CNS involvement. 19. Subjects who are unable or unwilling to comply with the requirements of clinical trial or other reasons that are not suitable for participating in the clinical trial. 20. Subjects who have received major surgery 2 weeks prior to the screening or plan to receive major surgery within 4 weeks after study treatment (excluding cataract and other local anesthesia).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Biological
CT0594CP

Locations

Country Name City State
China Shanghai Tongji Hospital Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Aibin Liang,MD,Ph.D. CARsgen Therapeutics Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability dose limiting toxicity Safety and tolerability: dose limiting toxicity [Time Frame: 21-28 days post administration of CT0594CP ] 21-28 days
Secondary Pharmacokinetics of CT0594CP CAR-T Cells (Tmax) peak plasma Concentration time(Tmax), of after infusion CT0594CP CAR T Cells From first dose of study drug adminisration to end of treatment (up to 12 months)
Secondary Pharmacokinetics of CT0594CP CAR-T Cells (Cmax) peak plasma Concentration(Cmax), of after infusion CT0594CP CAR T Cells From first dose of study drug adminisration to end of treatment (up to 12 months)
Secondary Pharmacokinetics of CT0594CP CAR-T Cells (AUC) area under the Plasma concentration versus time curve (AUC), of after infusion CT0594CP CAR T Cells From first dose of study drug adminisration to end of treatment (up to 12 months)
Secondary To evaluate the overall safety and tolerability of CT0594CP Post-treatment Adverse events (TEAE) and incidence, Special Concern Adverse Events (AESI) and incidence, treatment-related adverse events From first dose of study drug administration to end of treatment (up to 12 months)
Secondary To evaluate the initial efficacy of CT0594CP infusion in target subjects Overall response rate (ORR)? Complete response/strict complete response (CR/sCR) rate?Response rates of VGPR and above were achieved
?Duration of response (DOR)?Progression-free survival (PFS)?Overall survival (overall survival (OS)?Minimal residual disease (MRD) negative rate as measured by International Myeloma Working Group (IMWG) criteria after CT0594CP infusion
From first dose of study drug administration to end of treatment (up to 12 months)
See also
  Status Clinical Trial Phase
Recruiting NCT03140943 - Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 2
Recruiting NCT05066022 - A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma N/A
Recruiting NCT06182696 - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM Phase 1/Phase 2
Recruiting NCT03715478 - Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex Phase 1/Phase 2
Completed NCT02917941 - A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03903406 - Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
Completed NCT03242460 - The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Phase 2
Terminated NCT03836053 - Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma Phase 1
Recruiting NCT05719701 - Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Recruiting NCT05297240 - Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Terminated NCT04272775 - A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Phase 1
Not yet recruiting NCT06351644 - ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Withdrawn NCT04392648 - A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 1
Active, not recruiting NCT01632150 - Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Phase 2
Completed NCT02831686 - A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma Phase 1
Recruiting NCT06153251 - A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Phase 1
Completed NCT00882063 - Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04017130 - A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT03416374 - A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Phase 4
Recruiting NCT05486975 - This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. Early Phase 1